Stocksigma LogoStocksigma Logo

Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance

Piramal Pharma reported consolidated Q2FY27 revenue of ₹2,617 Cr, up 28% YoY, led by CDMO (+36%) and CHG (+32%)

Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance

Piramal Pharma Ltd · Investor Presentation · 28 Oct 2026, 2:36 am

Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance Piramal Pharma reported consolidated Q2FY27 revenue of ₹2,617 Cr, up 28% YoY, led by CDMO (+36%) and CHG (+32%). EBITDA surged 72% YoY to ₹385 Cr, with margins expanding 372 bps YoY to 14.7% due to operational leverage and cost optimization. PAT turned positive to ₹5 Cr versus a ₹99 Cr loss in Q2FY26. H1FY27 revenue rose 23% YoY to ₹4,887 Cr. Management raised its FY27 revenue growth guidance to 19–20%, expecting meaningfully higher profitability as H2 is typically stronger.

Original exchange filing (PDF)

More announcements from Piramal Pharma Ltd

All Piramal Pharma Ltd announcements